BACKGROUND: With the increasing diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) at earlier stages and new therapies, there is a rising demand for tools to stratify risk and prognosis. We ...

The partnership will see Viz.ai develop an AI Care Pathway for cardiac amyloidosis.

Ellipsis Health partners with PromptWell to boost enrollment in patient care programs, while CaryHealth teams up with ...

A report from the World Heart Federation provides an overview of transthyretin amyloid cardiomyopathy (ATTR-CM), including tools for diagnosis and patient management, highlighting the importance of ...

A type of heart failure caused by a build-up of amyloid can be accurately diagnosed and prognosticated with an imaging technique, eliminating the need for a biopsy, according to a multicenter study ...

A blood biomarker for Alzheimer's disease also indicates damage to the heart and kidneys, complicating early and clinical ...

Cardiac amyloidosis, once regarded as a rare and elusive cause of heart failure, has rapidly emerged as a critical diagnosis among patients presenting with ...

The Chattanooga Heart Institute announces the opening of its new Martin Cardiac Amyloidosis Center of Excellence in honor of Dr. Henry Cheng, the first of its kind in the region. This specialized ...

March is recognized as Amyloidosis Awareness Month, yet for many in the Black community, this disease remains largely unknown ...

Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission ...

Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam ...